BiotechTube

ISV-305

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Inflammation and Pain Associated With Cataract Surgery

Conditions

Inflammation and Pain Associated With Cataract Surgery

Trial Timeline

Jan 3, 2018 → Nov 18, 2019

NCT ID
NCT03192150

About ISV-305

ISV-305 is a phase 3 stage product being developed by Sun Pharmaceutical for Inflammation and Pain Associated With Cataract Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT03192150. Target conditions include Inflammation and Pain Associated With Cataract Surgery.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT01543490Phase 3Completed
NCT03192137Phase 3Completed
NCT03192150Phase 3Completed

Competing Products

20 competing products in Inflammation and Pain Associated With Cataract Surgery

See all competitors
ProductCompanyStageHype Score
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303Sun PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterolMerckPhase 1
33
MAS825 + PlaceboNovartisPhase 2
52
Secukinumab s.c. injectionNovartisApproved
85
etanerceptAmgenPhase 3
76
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0114-0006 + placeboNovo NordiskPhase 2
51
NNC0114-0006 + placeboNovo NordiskPhase 1
32
NNC0109-0012 + placeboNovo NordiskPhase 2
51
NNC 0151-0000-0000 + NNC 0151-0000-0000 + placeboNovo NordiskPhase 1
32
catridecacog + placeboNovo NordiskPhase 2
51
NNC109-0012 + placeboNovo NordiskPhase 2
51
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0215-0384 + placeboNovo NordiskPhase 1
32
NNC 0151-0000-0000 + placeboNovo NordiskPhase 2
51
NNC0109-0012 + placeboNovo NordiskPhase 2
51

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85